First Horizon (NYSE:FHN) Q3 2025 Earnings Call October 15, 2025 09:30 AM ET Company ParticipantsBryan Jordan - Chairman, President, and CEOTyler Craft - Head of Investor RelationsHope Dmuchowski - CFOThomas Hung - Chief Credit OfficerConference Call ParticipantsAndrew Leischner - AnalystTimur Braziler - AnalystBen Gerlinger - AnalystJared Shaw - AnalystJanet Lee - AnalystJon Arfstrom - AnalystNick Holowko - AnalystCasey Haire - AnalystNone - AnalystChristopher Marinac - AnalystAnthony Elian - AnalystModerat ...

Financial Data and Key Metrics Changes - The company reported an adjusted earnings per share (EPS) of $0.51, a $0.06 increase from the previous quarter [5] - Adjusted return on tangible common equity increased by 135 basis points to 15% [5] - Net interest income (NII) grew by $33 million, with a 15 basis point expansion of net interest margin to 3.55% [6][5] - Average rate paid on interest-bearing deposits increased to 2.78%, up from 2.76% in the previous quarter [6] Business Line Data and Key Metrics Changes - Period-end loans decreased slightly, with loans to mortgage companies down $132 million, consistent with seasonal trends [7] - The commercial and industrial (CNI) portfolio saw an increase of $174 million quarter over quarter [8] - Fee income increased by $26 million from the prior quarter, driven by improved business conditions [8] - Adjusted expenses increased by $45 million from the previous quarter, primarily due to personnel expenses and outside services [9] Market Data and Key Metrics Changes - Period-end deposit balances decreased by $52 million, driven by a decrease in brokered CDs, but non-interest-bearing deposits increased by $131 million [6] - The company retained approximately 97% of the $29 billion in balances associated with clients who had a repricing event [6] Company Strategy and Development Direction - The company is focused on achieving sustainable growth and profitability while maintaining safety and soundness [4] - There is an emphasis on integrating potential mergers and acquisitions (M&A) that align with the company's existing footprint and culture [16] - The company aims to drive additional pre-tax net revenue of over $100 million through efficiency and revenue enhancements [12][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth due to increased client confidence and the potential for further Fed rate cuts [15] - The company is confident in its ability to achieve a sustainable 15% plus adjusted return on tangible common equity [17] - Management noted that the competitive environment for deposits is heating up, and they are focused on retaining existing clients while attracting new ones [6][33] Other Important Information - The company ended the quarter with a Common Equity Tier 1 (CET1) ratio of 11%, flat quarter over quarter [10] - Share buybacks accelerated to $190 million, with approximately 8.6 million shares repurchased [12] Q&A Session Summary Question: How optimistic is the company on growth and is there a noticeable change from a quarter ago? - Management noted increased confidence and noticeable changes in client behavior, with pipelines building throughout the quarter [22] Question: What is the outlook for the margin in the fourth quarter? - Management indicated that the margin may stabilize in the high 330s to low 340s, adjusting for one-time items [23] Question: What is driving the decline in core deposits? - Management explained that the industry is experiencing a mix shift, with clients moving funds into brokerage accounts, but they maintain a high retention rate of existing clients [33] Question: What are the company's M&A considerations? - Management emphasized a focus on organic growth but remains open to opportunistic M&A if the right opportunity arises [39][40] Question: How does the company view its capital position and buyback strategy? - Management stated that buybacks will be contingent on loan growth, with a focus on deploying capital effectively [98]

Financial Data and Key Metrics Changes - Morgan Stanley reported record revenues of $18.2 billion and earnings per share (EPS) of $2.8 for Q3 2025, with a return on tangible equity (RoTCE) of 23.5% [3][11] - The year-to-date efficiency ratio stood at 69%, indicating strong operational leverage [11] - Total client assets across Wealth and Investment Management increased by $1.3 trillion year-over-year, reaching $8.9 trillion [5][11] Business Line Data and Key Metrics Changes - Institutional Securities revenues were $8.5 billion, with investment banking revenues increasing to $2.1 billion, marking a year-over-year growth of over 50% [13][14] - Wealth Management achieved record revenues of over $8 billion, with a reported margin of 30.3% [19][21] - Investment Management saw total assets under management (AUM) reach $1.8 trillion, with long-term net inflows of $16.5 billion in the quarter [25][27] Market Data and Key Metrics Changes - The Americas led year-over-year growth in Institutional Securities, with strong performance noted in Asia due to renewed investor appetite [13][14] - The equity underwriting market showed significant activity, with revenues increasing 80% year-over-year to $652 million [15] - Fixed income underwriting revenues were $772 million, driven by higher loan issuance [15] Company Strategy and Development Direction - Morgan Stanley's strategy focuses on raising, managing, and allocating capital, with an emphasis on maintaining earnings durability and driving growth through investment in technology and integrated services [4][9] - The company is actively investing in its wealth and investment management capabilities, including partnerships in private markets and digital assets [20][24] - The firm aims to reach $10 trillion in total client assets as part of its growth trajectory [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the sustainability of investment banking trends, citing a favorable regulatory backdrop and a strong pipeline across regions [32][34] - The firm anticipates continued growth in wealth management driven by workplace migration and IPO activity [38][50] - Management acknowledged the potential for net interest income growth despite a declining rate environment, supported by consistent lending balances [95][96] Other Important Information - Morgan Stanley's CET1 capital ratio stands at 15.2%, with excess capital over 300 basis points [7][28] - The firm is committed to returning capital to shareholders through dividends and share buybacks while focusing on organic growth opportunities [73][80] Q&A Session Summary Question: Sustainability of Investment Banking Trends - Management noted that while it is uncertain if a "golden age" in investment banking is upon us, there are positive signs of growth across various industry groups and regions [31][32] Question: Net New Assets Growth in Wealth Management - Management highlighted strong performance across all channels, with significant contributions from workplace migration and IPOs, exceeding previous expectations [34][38] Question: Sustainability of 30% Pretax Margin - Management emphasized the importance of continued investment in the wealth business to maintain and potentially exceed the 30% margin, viewing it as an output of their investment strategy [42][43] Question: AI's Impact on Business - Management discussed various applications of AI to enhance efficiency and productivity across the firm, indicating that they are just beginning to explore its full potential [46][49] Question: Growth Opportunities in Wealth Management - Management acknowledged the potential for growth in private markets and the importance of educating clients about new products, indicating a long-term growth opportunity [50][52] Question: Capital Deployment for Growth - Management reiterated a focus on organic growth through internal investments while remaining open to inorganic opportunities that align with their strategic goals [72][76]

Financial Data and Key Metrics Changes - The company reported an adjusted earnings per share (EPS) of $0.51, a $0.06 increase from the previous quarter [5] - Adjusted return on tangible common equity increased by 135 basis points to 15% [5] - Net interest income (NII) grew by $33 million, with a 15 basis point expansion of net interest margin to 3.55% [5][6] - Average rate paid on interest-bearing deposits increased to 2.78%, up from 2.76% in the previous quarter [6] Business Line Data and Key Metrics Changes - The loan portfolio saw a slight decrease, with loans to mortgage companies down $132 million, consistent with seasonal trends [7] - Commercial and industrial (CNI) portfolio increased by $174 million quarter over quarter [8] - Fee income increased by $26 million from the prior quarter, driven by improved business conditions [8] - Adjusted expenses increased by $45 million from the previous quarter, primarily due to personnel expenses and outside services [9] Market Data and Key Metrics Changes - Period-end deposits decreased by $52 million, driven by a $652 million decrease in brokered CDs, but non-interest-bearing deposits increased by $131 million [6] - The company retained approximately 97% of the $29 billion in balances associated with clients who had a repricing event [6] Company Strategy and Development Direction - The company aims to achieve a sustainable 15% plus adjusted return on tangible common equity [12] - Focus on executing initiatives that could generate over $100 million in additional pre-tax net revenue [15] - The company is optimistic about capitalizing on profitable loan growth due to recent Fed rate cuts [14] Management's Comments on Operating Environment and Future Outlook - Management noted increased client confidence and pipeline momentum, despite potential impacts from tariff uncertainties [19] - The company is confident in its ability to integrate a well-structured merger if opportunities arise in 2026 or beyond [15] - The outlook for charge-offs and taxes remains unchanged as the year closes [12] Other Important Information - The company ended the quarter with a Common Equity Tier 1 (CET1) ratio of 11%, flat quarter over quarter [10] - Share buybacks accelerated to $190 million, with approximately 8.6 million shares repurchased [11] Q&A Session Summary Question: How optimistic is the company on growth, and is there a noticeable change from a quarter ago? - Management noted a noticeable increase in client confidence and pipeline momentum, with lower rates contributing positively [19] Question: What is the expected margin for the fourth quarter? - The CFO indicated that the margin would likely be in the high 330s to low 340s, adjusting for one-time items [20] Question: What is driving the decline in core deposits? - Management explained that the industry is experiencing a shrinkage in deposits, with a focus on retaining existing clients and attracting new ones [28] Question: What are the company's M&A considerations? - Management emphasized a focus on organic growth but acknowledged the potential for opportunistic M&A if suitable opportunities arise [34][41] Question: How does the company plan to achieve the 15% ROCI target? - The strategy includes reducing capital, normalizing credit costs, and leveraging existing client relationships for revenue growth [66]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [6][7][16] - Adjusted earnings per share of $1.30 was in line with consensus estimates, and foreign exchange had a favorable year-over-year impact of 1.4% on third quarter sales [16][17] - Adjusted gross margin was 55.8% of sales, reflecting a decrease due to tariffs, while adjusted operating margin increased by 40 basis points to 23% of sales [16][17] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in adult nutrition products like Ensure and Glucerna [8][9] - Diagnostics saw modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China, while point-of-care diagnostics grew by 8% [9][10] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets, with strong contributions from therapeutic areas like gastroenterology and cardiometabolic [10][11] - Medical devices experienced a 12.5% sales growth, driven by double-digit growth in diabetes care and cardiac rhythm management [11][12] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while Europe saw growth of 6% to 7%, and Latin America grew in the mid-teens [46][47] - In China, the company faced headwinds from VBP pricing dynamics, but growth in other segments like EPD and nutrition remained strong, with overall growth in China around 5% to 7% when excluding diagnostics [65][66] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and easing headwinds from diagnostics [20][25] - Investments in innovation and a robust pipeline are expected to drive future growth, with nearly 200 clinical trials planned for next year [24][25] - The company is focused on expanding its market share in key segments, including diabetes care and cardiac rhythm management, with new product launches like Volt and dual analyte sensors [22][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and new product launches as key growth drivers [20][21] - The company anticipates a recovery in the diagnostics business as headwinds from China moderate and new products are rolled out [48] - Management highlighted the importance of addressing barriers to CGM penetration in the basal segment and emphasized ongoing efforts to increase awareness among primary care physicians [78][80] Other Important Information - Recent product launches contributed nearly half a billion dollars in sales this quarter, adding over 100 basis points to organic sales growth [8] - The company is advancing its biosimilars strategy, with several regulatory approvals expected in the near future [10] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting continued growth driven by product momentum and easing headwinds [20] Question: U.S. diabetes growth dynamics - U.S. diabetes care grew 19%, with expectations for strong growth next year driven by new product launches [29][32] Question: Diagnostics business headwinds - Management acknowledged challenges in the diagnostics segment due to VBP in China but expects a recovery as these headwinds moderate [44][48] Question: Cardiac rhythm management growth - The cardiac rhythm management segment is experiencing significant growth, with expectations for continued market share gains [67][69] Question: Structural heart market outlook - Management is optimistic about the structural heart market, particularly with upcoming product launches and competitive advancements [75][76]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [6][7][16] - Adjusted gross margin was 55.8% of sales, showing a decrease from the prior year due to tariffs, while adjusted operating margin increased by 40 basis points to 23% of sales [16][52] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in the adult nutrition segment [8][9] - Diagnostics experienced modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China [9][10] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets [10] - Medical devices saw a 12.5% sales growth, with significant contributions from diabetes care and electrophysiology [11][12] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while Europe saw growth of 6% to 7%, and Latin America experienced mid-teens growth [46] - In China, the company faced challenges due to VBP pricing dynamics, but growth in other segments remained stable, with a projected growth rate of 5% to 7% excluding diagnostics [65][66] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and a strong existing portfolio [20][25] - Investments in innovation and clinical trials are expected to drive future growth, with nearly 200 clinical trials planned for next year [24][25] - The company is focused on expanding its market share in key segments, including diabetes care and cardiac rhythm management [68][69] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [20][21] - The company anticipates a recovery in the diagnostics business, particularly outside of China, and expects to see improved performance in 2026 [48][66] Other Important Information - Recent product launches contributed nearly half a billion dollars in sales this quarter, enhancing organic sales growth [8] - The company is advancing its biosimilars strategy, with several regulatory approvals expected in the near future [10] Q&A Session Summary Question: Thoughts on next year's sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting continued growth driven by product momentum and easing headwinds [20][21] Question: Insights on diabetes growth in the U.S. and internationally - U.S. diabetes care grew 19%, with expectations for strong growth next year driven by new product launches [29][31] Question: Updates on the diagnostics business and recovery expectations - Management noted that while challenges remain in China, the diagnostics business outside of China is expected to accelerate, with a recovery anticipated next year [46][48] Question: Performance of the electrophysiology franchise - The electrophysiology segment is experiencing double-digit growth, with positive feedback on new products like the Volt catheter [35][36] Question: Outlook for the cardiac rhythm management market - The dual chamber leadless pacemaker market is expected to grow significantly, with current penetration rates indicating substantial room for growth [68][69] Question: Update on structural heart and left atrial appendage closure - Management is optimistic about future growth in left atrial appendage closure, with new product trials expected to yield positive results [74][75]

Financial Data and Key Metrics Changes - The company reported EPS growth of $0.13 sequentially, or 14% [4] - Net Interest Income (NII) grew by 3.5% sequentially, driven by a 5 basis point expansion in Net Interest Margin (NIM) [4][10] - Fee growth was 5% compared to Q2, with a record performance in capital markets [4][12] - The Common Equity Tier 1 (CET1) ratio increased by 10 basis points to 10.7% [4][18] - The company achieved a positive operating leverage of 3% with expense growth held to just 1% [4][9] Business Line Data and Key Metrics Changes - The private bank saw a significant increase in deposits, growing by $3.8 billion to $12.5 billion, surpassing the year-end target of $12 billion [5][19] - The private bank contributed $0.08 to EPS this quarter, up from $0.06 in the prior quarter [11] - Capital markets delivered a record third quarter, with strong performance across all categories [10][13] - The wealth business achieved record advisory fees due to strong inflows and market appreciation [14] Market Data and Key Metrics Changes - Average deposits increased by 1%, driven by growth in the private bank and commercial sectors [16] - Non-interest-bearing balances rose by about $1.5 billion or 4%, maintaining a steady mix at 22% of the total deposits [16] - Net charge-offs decreased to 46 basis points from 48 basis points in the prior quarter, indicating favorable credit trends [17] Company Strategy and Development Direction - The company is focused on executing strategic initiatives, particularly in the private bank and private wealth sectors, aiming for superior organic EPS growth relative to peers [8][18] - The "Reimagine the Bank" initiative is underway, with expectations for net benefits to positively impact results starting in 2027 [6][22] - The company aims to build a top-performing bank by enhancing customer service and operational efficiency [9][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum into 2026, despite macroeconomic uncertainties [8][25] - The outlook for Q4 includes continued attractive earnings growth, driven by positive operating leverage and favorable credit trends [8][24] - The company remains focused on executing its strategic agenda while navigating a dynamic environment [25] Other Important Information - The Board of Directors declared a quarterly dividend of $0.46, reflecting a 9.5% increase [9] - The company executed $75 million in stock buybacks during the quarter [10][18] - The private bank is expected to double its contribution to the bottom line within the next three years [51] Q&A Session Summary Question: Expected margin trajectory - Management forecasts a margin of $305 for Q4, with a medium-term target of $325-$350, influenced by various factors including asset sensitivity and pricing spreads [30][32] Question: Role of M&A in the company's future - The company is focused on organic growth through the private bank and does not foresee significant M&A activity unless high-value opportunities arise [34][35] Question: Private bank outlook and AUM targets - Management is confident in achieving deposit growth but acknowledges that AUM targets may depend on the timing of liftouts [42][44] Question: Sensitivity of Fed funds to margin - Management has layered in hedges to protect against aggressive Fed cuts, maintaining a balanced view on interest rate risks [54][62] Question: Cost-saving opportunities related to "Reimagine the Bank" - The company is exploring various cost-saving measures, including vendor simplification and optimizing branch networks, to fund investments [63][67]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5%, excluding COVID test sales, with earnings per share rising to $1.3, reflecting high single-digit growth compared to last year [6][7][18] - Adjusted gross margin was 55.8% of sales, reflecting a decrease due to tariffs, while adjusted operating margin increased by 40 basis points to 23% [19][18] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by adult nutrition, particularly in international markets with a 10% growth [8][9] - Diagnostics experienced modest sales growth, with core lab diagnostics growing 7% excluding China, while point of care diagnostics grew by 8% [10][11] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets [12] - Medical Devices sales grew by 12.5%, with significant contributions from diabetes care and electrophysiology [12][16] Market Data and Key Metrics Changes - International markets for adult nutrition saw a 10% growth, while the U.S. diagnostics market grew by 10% [9][59] - The European diagnostics market grew by 6-7%, and Latin America experienced mid-teens growth [61] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, focusing on new product launches and addressing headwinds in diagnostics [24][27] - Investments in clinical trials and product launches are expected to drive future growth, with a commitment to maintaining a robust pipeline [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [22][24] - The company anticipates a recovery in the diagnostics business, particularly outside of China, with expectations for mid to high single-digit growth next year [58][62] Other Important Information - The company is advancing its biosimilar strategy and has made progress in regulatory approvals for several products [12] - The management highlighted the importance of maintaining a full portfolio to drive growth across various segments [50] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting to deliver similar growth rates as in 2025 [22][24] Question: U.S. diabetes growth dynamics - U.S. diabetes care grew by 19%, with expectations for continued strong growth driven by new product launches [32][35] Question: Drivers of diagnostics business recovery - Management noted that while challenges remain in China, growth outside of China is accelerating, with expectations for a recovery in the diagnostics business [58][62] Question: Structural heart market outlook - Management acknowledged the importance of left atrial appendage closure and is optimistic about future growth in this area [96][100] Question: Barriers to CGM penetration in the U.S. - Management identified the need for increased awareness and coverage among primary care physicians as barriers to higher CGM penetration [101][106]

Citizens Financial Group (NYSE:CFG) Q3 2025 Earnings Call October 15, 2025 09:00 AM ET Speaker6Good morning, everyone, and welcome to the Citizens Financial Group Third Quarter 2025 Earnings Conference Call. My name is Denise, and I'll be your operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a brief question and answer session. As a reminder, this event is being recorded. Now, I'll turn the call over to Kristin Silberberg, Head of Investor Re ...

Financial Data and Key Metrics Changes - Total net sales for Q3 2025 were €7.5 billion, within guidance, with net system sales at €5.6 billion, including €2.1 billion from EUV system sales and €3.4 billion from non-EUV system sales [6][7] - Gross margin for the quarter was 51.6%, and net income was €2.1 billion, representing 28.3% of total net sales, resulting in an EPS of €5.49 [7][8] - The effective tax rate for Q3 was 17.8%, with an expected annualized effective tax rate of around 17% for the full year [7] - Cash, cash equivalents, and short-term investments at the end of Q3 were €5.1 billion [7] Business Line Data and Key Metrics Changes - Installed Base Management sales for the quarter were €2 billion, as guided [7] - Net system bookings for Q3 were €5.4 billion, with €3.6 billion from EUV systems and €1.8 billion from non-EUV systems [8] - Net system bookings were slightly weighted towards Logic at 53%, while Memory accounted for 47% [8] Market Data and Key Metrics Changes - The company expects Q4 total net sales to be between €9.2 billion and €9.8 billion, with installed base management sales around €2.1 billion [9] - The company anticipates a strong Q4, similar to the previous year, with a gross margin expected between 51% and 53% [9] Company Strategy and Development Direction - The company is focusing on advancing its technology roadmap, particularly in EUV and 3D integration, to meet customer demands [12][14] - A strategic partnership with Mistral AI was announced, aiming to embed AI across the company's portfolio to enhance performance and productivity [16] - The company expects a shift towards more advanced Logic and DRAM applications, which will require intensive use of advanced lithography systems [18] Management's Comments on Operating Environment and Future Outlook - Management noted a positive news flow in the industry, particularly regarding AI infrastructure investments, which supports demand in leading-edge logic and advanced DRAM [10] - There is an expectation of a significant decline in China customer demand in 2026 compared to strong business in 2024 and 2025, but overall sales are not expected to fall below 2025 levels [11] - The company is preparing for growth and has been investing in capacity to meet future demand [50][66] Other Important Information - The company paid an interim dividend of €1.6 per ordinary share in Q3, with another expected in Q4 [8] - A new share buyback program is expected to be announced in January 2026 [8] Q&A Session Summary Question: Can you elaborate on the positive news that helped reduce uncertainty? - Management highlighted positive developments in AI infrastructure investments, which create a backlog of opportunities for future orders [21][22] Question: What is the visibility for 2026 regarding orders and capacity? - Management indicated that while there is some clarity, it is still early to predict exact impacts for 2026, especially concerning customer demand in China [25][26] Question: How do you view the strength in DRAM and its implications for EUV? - Management stated that the transition to 4F2 DRAM architecture is not expected to reduce EUV layer counts, and they anticipate growth in EUV layers [33][34] Question: What is the outlook for gross margin in 2026? - Management noted that product mix and the expected increase in EUV sales would influence gross margin, but specific guidance would be provided in January [90][91] Question: How is the installed base business expected to develop going into 2026? - Management observed that the service business is growing alongside the installed base, and they will provide updates on upgrade business expectations in January [96][98] Question: How is the company preparing for potential supply limitations in the AI market? - Management emphasized the importance of maintaining dialogue with customers to ensure timely adjustments to production capacity [66][68]